RE
SPRO icon

RBC Europe’s Spero Therapeutics SPRO Stock Holding History

RBC Europe’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-478
Closed -$8.8K – 1077
2021
Q3 		$8.8K Hold
478
– – ﹤0.01% 960
2021
Q2 		$6.67K Hold
478
– – ﹤0.01% 1016
2021
Q1 		$7.04K Hold
478
– – ﹤0.01% 960
2020
Q4 		$9.27K Hold
478
– – ﹤0.01% 890
2020
Q3 		$5.33K Sell
478
-210
-31% -$2.48K ﹤0.01% 900
2020
Q2 		$9.31K Hold
688
– – ﹤0.01% 782
2020
Q1 		$5.56K Buy
688
+90
+15% +$793 ﹤0.01% 819
2019
Q4 		$5.75K Hold
598
– – ﹤0.01% 894
2019
Q3 		$6.34K Hold
598
– – ﹤0.01% 866
2019
Q2 		$6.88K Buy
598
+153
+34% +$1.84K ﹤0.01% 868
2019
Q1 		$5.7K Hold
445
– – ﹤0.01% 914
2018
Q4 		$2.74K Hold
445
– – ﹤0.01% 975
2018
Q3 		$4.68K Buy
+445
New +$5.17K ﹤0.01% 970

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RBC Europe's SPRO Position: Q4 2021 in Review

RBC Europe sold out of Spero Therapeutics (SPRO) in Q4 2021, closing a stake of 478 shares — an estimated $8.8K sold.

RBC Europe first reported a position in SPRO in Q3 2018 and held it in 13 quarters. The position peaked at $9.31K in Q2 2020. 84 funds tracked by Wall St. Rank hold SPRO as of Q4 2021.

  • RBC Europe reported no remaining Spero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 478 Spero Therapeutics shares in Q4 2021, an estimated $8.8K.
  • RBC Europe first reported a position in Spero Therapeutics in Q3 2018 and held it in 13 quarters.
  • RBC Europe's Spero Therapeutics position peaked at $9.31K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.